Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

143.18 +2.47 (+1.76%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

This Triumph Group Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday ↗

April 15, 2025

Via Benzinga

Looking for growth without the hefty price tag? Consider NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). ↗

April 11, 2025

Based on Fundamental Analysis it can be said that NASDAQ:NBIX is a growth stock which is not overvalued.

Via Chartmill

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is an undervalued gem with solid fundamentals. ↗

April 09, 2025

Discover NEUROCRINE BIOSCIENCES INC, an undervalued stock. NASDAQ:NBIX showcases solid financial health and profitability while maintaining an appealing valuation.

Via Chartmill

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—A High-Growth Stock Gearing Up for Its Next Upward Move. ↗

March 27, 2025

Based on a technical and fundamental analysis of NASDAQ:NBIX we can say: NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.

Via Chartmill

Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential ↗

March 26, 2025

Via The Motley Fool

Assessing Neurocrine Biosciences: Insights From 15 Financial Analysts ↗

February 21, 2025

Via Benzinga

Why Neurocrine Biosciences Stock Sank Today ↗

February 10, 2025

Via The Motley Fool

Why the quality investor may take a look at NASDAQ:NBIX. ↗

February 07, 2025

A fundamental analysis of (NASDAQ:NBIX): Analyzing the Quality Characteristics of NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX).

Via Chartmill

Deep Dive Into Neurocrine Biosciences Stock: Analyst Perspectives (14 Ratings) ↗

March 26, 2025

Via Benzinga

Despite its growth, NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) remains within the realm of affordability. ↗

March 21, 2025

NASDAQ:NBIX is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced.

Via Chartmill

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

March 12, 2025

NEUROCRINE BIOSCIENCES INC has a stellar value proposition. NASDAQ:NBIX not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point.

Via Chartmill

NASDAQ:NBIX is showing decent growth, but is still valued reasonably. ↗

February 26, 2025

NASDAQ:NBIX is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced.

Via Chartmill

Estee Lauder, Moderna And PayPal Are Among Top 10 Large Cap Losers Last Week (Feb 3-Feb 7): Are The Others In Your Portfolio? ↗

February 09, 2025

Skyworks Solutions, Estee Lauder, Venture Global, Neurocrine Biosciences, Moderna, Illumina, IDEX Corporation, PTC Inc, PayPal Holdings, Skechers U.S.A. and Avantor were worst performers, fell up to...

Via Benzinga

Earnings Summary: Neurocrine Biosciences Q4 ↗

February 06, 2025

Via Benzinga

Earnings Scheduled For February 6, 2025 ↗

February 06, 2025

Via Benzinga

Neurocrine Biosciences Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) ↗

February 04, 2025

Via Benzinga

Why Is Neurocrine Biosciences Stock Trading Lower On Friday? ↗

February 07, 2025

Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth despite near-term challenges.

Via Benzinga

Neurocrine Biosciences Reports Mixed Q4 ↗

February 07, 2025

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates.

Via The Motley Fool

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

February 07, 2025

Via Benzinga

Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug ↗

February 06, 2025

Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza.

Via Investor's Business Daily

Looking for growth without the hefty price tag? Consider NASDAQ:NBIX. ↗

February 05, 2025

Discover NEUROCRINE BIOSCIENCES INC, an undervalued growth gem. NASDAQ:NBIX is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an...

Via Chartmill

Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout. ↗

January 07, 2025

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) qualifies as a high growth stock and is consolidating.

Via Chartmill

NASDAQ:NBIX: good value for what you're paying. ↗

January 03, 2025

Investors should take notice ofNEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—it offers a great deal for the fundamentals it presents.

Via Chartmill

NASDAQ:NBIX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

January 30, 2025

NEUROCRINE BIOSCIENCES INC may be an undervalued stock option. NASDAQ:NBIX retains a strong financial foundation and an attractive price tag.

Via Chartmill

Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights ↗

January 28, 2025

Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal.

Via Benzinga

NASDAQ:NBIX stands out as a growth opportunity that won't break the bank. ↗

January 15, 2025

Investors seeking growth at a reasonable cost should explore NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX).

Via Chartmill

Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Deserves Consideration as a Quality Investment. ↗

January 13, 2025

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Exhibits Quality Stock Traits. Here's Why.

Via Chartmill

Neurocrine Biosciences Stock Sees RS Rating Upgrade ↗

December 24, 2024

Neurocrine Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 67 to 71.

Via Investor's Business Daily

While growth is established for NASDAQ:NBIX, the stock's valuation remains reasonable. ↗

December 24, 2024

NASDAQ:NBIX stands out as a growth opportunity that won't break the bank.

Via Chartmill

Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio? ↗

December 22, 2024

The top-performing stocks last week were TEVA, KVYO, DRI, DOCS, BIRK, JBL, NBIX, GME, RDY, and LI. Did you have any of them in your portfolio?

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.